Company intelligence / Profile preview

Revelation Biosciences

San Diego, California, United Statesrevbioscience.com ↗

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Revelation Biosciences has developed Gemini, an intravenously administered proprietary formulation of PHAD®, which aims to reduce inflammation by reprogramming the innate immune response. The lead programs target acute kidney injury and chronic kidney disease. Recent news highlights ongoing development for infection management in severe burn patients. No late-stage clinical results are reported as of June 2025.

Therapeutic areas: NephrologyInfectious Diseases
Modalities: Small moleculeImmunomodulator
Industry: Biotech

Beyond the preview

Go deeper on Revelation Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revelation Biosciences.

Explore the full profile